- Surveillance using regular imaging, tumor biomarkers, or both together was not associated with improved OS compared with history taking and physical examination (H&P; symptom based) evaluations after curative surgical resection of pancreatic cancer.
Why this matters
- 2 US-based guidelines recommend intensified surveillance, whereas 3 European guidelines recommend against because of a lack of evidence that it prolongs survival.
- Retrospective, single-center analysis of recurrent or metastatic pancreatic cancer (n=181).
- Groups included H&P only, H&P+imaging, H&P+biomarker, and H&P+imaging+biomarker.
- Funding: Taiwan government.
- Median OS (P=.670):
- H&P only: 21.4 months.
- H&P/imaging: 13.9 months.
- H&P/biomarker: 20.5 months.
- H&P/imaging+biomarker: 16.5 months.
- Median relapse-free survival (P=.259):
- H&P only: 11.7 months.
- H&P/imaging: 6.3 months.
- H&P/biomarker: 9.3 months.
- H&P/imaging+biomarker: 6.9 months.
- Median postrecurrence OS (P=.953):
- H&P only: 6.9 months.
- H&P/imaging: 7.5 months.
- H&P/biomarker: 5.0 months.
- H&P/imaging+biomarker: 7.8 months.
- Risk factors affecting OS:
- Eastern Cooperative Oncology Group Performance Status (0 vs ≥1; HR, 0.516; P=.020).
- Primary tumor site: head/body vs tail; HR, 0.599; P=.049.
- Tumor grade: good/moderate vs poor differentiation; HR, 0.553; P=.032.
- Taiwanese population.